The Efficacy of Nigella Sativa Versus VitaminD3 as Supplement Therapy in Coronavirus Disease 2019 (COVID-19) (COVID-19)
Covid19
About this trial
This is an interventional treatment trial for Covid19
Eligibility Criteria
Inclusion Criteria:
- Patients with mild-moderate COVID-19 according to the classification (Table 1)
- Adult (18 - 65 years old).
- Polymerase chain reaction (PCR)-confirmed infection with Severe Acute Respiratory Syndrome Coronavirus-2.
Exclusion Criteria:
- Patients with severe illness requiring admission to intensive care unit.
- Asymptomatic patients.
- Severe chronic kidney disease (i.e. estimated glomerular filtration rate < 30 mL/min) or end stage renal disease requiring dialysis
- Severe chronic liver disease (Alanine transaminase or Aspartate transaminase > 5 times the upper limit of normal).
- contraindications to any of the interventional drugs.
- Pregnancy or breast feeding.
- Allergy to any of the interventional.
Sites / Locations
- Respiratory System specialized hospital at Kobry Elobba Military Medical hospitals.Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
No Intervention
Active Comparator
Active Comparator
Active Comparator
group 1
group 2
group 3
group 4
Twenty five patients will be administered only the standard treatment regimen according to Ministry Of Health, and Population management protocol for COVID-19 patients (November 2020).
Twenty five patients will be administered a single dose (900mg) of Nigella Sativa capsule twice daily plus standard therapy
Twenty five patients will be administered a single dose (2000 IU) of vitamin D3 tablet once daily plus standard therapy
Twenty five patients will be administered a single dose (900 mg) of Nigella Sativa capsule twice daily, and single dose of vitamin D3 tablet (2000 IU) once daily plus standard therapy.